Allscripts Healthcare Solutions
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Allscripts Healthcare Solutions's revenues will increase 0.8% and EPS will expand 16.7%.
The average estimate for revenue is $367.5 million. On the bottom line, the average EPS estimate is $0.14.
Last quarter, Allscripts Healthcare Solutions notched revenue of $350.9 million. GAAP reported sales were 9.6% lower than the prior-year quarter's $388.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.16. GAAP EPS were -$0.15 for Q4 against $0.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 38.8%, 650 basis points worse than the prior-year quarter. Operating margin was -3.6%, much worse than the prior-year quarter. Net margin was -6.9%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $1.51 billion. The average EPS estimate is $0.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 433 members out of 462 rating the stock outperform, and 29 members rating it underperform. Among 117 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 110 give Allscripts Healthcare Solutions a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allscripts Healthcare Solutions is hold, with an average price target of $10.90.
Is Allscripts Healthcare Solutions the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Allscripts Healthcare Solutions to My Watchlist.